Berkson Medical | Allen Arthritis

Research site

(Unclaimed)

Location

997 Raintree Circle, Suite 120, Allen, Texas, United States of America

Site insights

Top conditions

Top treatments

Enpatoran

Afimetoran

BMS-986326

Upadacitinib

Cenerimod

ABBV-154

Parent organization

This site is a part of Berkson Medical

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 9 total trials

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS-1)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Active, not recruiting

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Cenerimod

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Active, not recruiting

Systemic Lupus Erythematosus

Other: Placebo

Drug: Afimetoran

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-1)

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active...

Enrolling

Cutaneous Lupus Erythematosus (CLE)

Systemic Lupus Erythematosus (SLE)

Drug: Standard of care (SoC)

Drug: Placebo

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome (Unity)

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Dise...

Active, not recruiting

Primary Sjogrens Disease

Biological: Efgartigimod PH20 SC

Other: Placebo PH20 SC

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's (EnVISage)

This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to backgroun...

Active, not recruiting

Sjogren Disease

Biological: Sibeprenlimab

Other: Placebo

Locations recently updated